OBJECTIVE: Recent studies have shown a relative risk reduction in the incidence of prostate cancer in patients taking metformin. However, there are conflicting findings on the effect of metformin on established cases of prostate cancer. In this study we evaluated the effect of metformin on survival and pathologic outcomes in established prostate cancer. MATERIALS AND METHODS: We retrospectively identified 12,052 patients who underwent radical prostatectomy between 1997 and 2010 at Mayo Clinic. Among these, 885 (7.3%) were diabetics, including 323 taking and 562 not taking metformin. Kaplan-Meier method was utilized to calculate rates of biochemical recurrence (BCR), systemic progression (SP), and all-cause mortality (ACM). Cox models were used to estimate the metformin hazard ratio (HR) adjusted for clinical and pathologic variables. RESULTS AND CONCLUSIONS: Median follow-up was 5.1 years. In univariate analysis, metformin HR (95% confidence intervals) was not significant for BCR (1.13 [0.84, 1.52]; P = 0.40), SP (1.37 [0.69, 2.72]; P = 0.37), and ACM (1.32 [0.84, 2.05]; P = 0.23). After adjusting for covariates of interest, the HRs for metformin among diabetics remained nonsignificant for BCR (0.91 [0.67, 1.24]; P = 0.55), SP (0.83 [0.39, 1.74]; P = 0.62); and ACM (1.16 [0.73, 1.86]; P = 0.53). No significant difference was seen between metformin users and nonusers in the final pathologic Gleason score (P = 0.33), stage (P = 0.1), rate of positive surgical margins (P = 0.29), or tumor volume (P = 0.76). Metformin use was not associated with a risk reduction in BCR, SP, or ACM. Besides presenting survival data, our results describing metformin's effect on final pathology are unique.
OBJECTIVE: Recent studies have shown a relative risk reduction in the incidence of prostate cancer in patients taking metformin. However, there are conflicting findings on the effect of metformin on established cases of prostate cancer. In this study we evaluated the effect of metformin on survival and pathologic outcomes in established prostate cancer. MATERIALS AND METHODS: We retrospectively identified 12,052 patients who underwent radical prostatectomy between 1997 and 2010 at Mayo Clinic. Among these, 885 (7.3%) were diabetics, including 323 taking and 562 not taking metformin. Kaplan-Meier method was utilized to calculate rates of biochemical recurrence (BCR), systemic progression (SP), and all-cause mortality (ACM). Cox models were used to estimate the metformin hazard ratio (HR) adjusted for clinical and pathologic variables. RESULTS AND CONCLUSIONS: Median follow-up was 5.1 years. In univariate analysis, metformin HR (95% confidence intervals) was not significant for BCR (1.13 [0.84, 1.52]; P = 0.40), SP (1.37 [0.69, 2.72]; P = 0.37), and ACM (1.32 [0.84, 2.05]; P = 0.23). After adjusting for covariates of interest, the HRs for metformin among diabetics remained nonsignificant for BCR (0.91 [0.67, 1.24]; P = 0.55), SP (0.83 [0.39, 1.74]; P = 0.62); and ACM (1.16 [0.73, 1.86]; P = 0.53). No significant difference was seen between metformin users and nonusers in the final pathologic Gleason score (P = 0.33), stage (P = 0.1), rate of positive surgical margins (P = 0.29), or tumor volume (P = 0.76). Metformin use was not associated with a risk reduction in BCR, SP, or ACM. Besides presenting survival data, our results describing metformin's effect on final pathology are unique.
Authors: Heath D Skinner; Vlad C Sandulache; Thomas J Ow; Raymond E Meyn; John S Yordy; Beth M Beadle; Alison L Fitzgerald; Uma Giri; K Kian Ang; Jeffrey N Myers Journal: Clin Cancer Res Date: 2011-11-16 Impact factor: 12.531
Authors: Andrew C Hsieh; Yi Liu; Merritt P Edlind; Nicholas T Ingolia; Matthew R Janes; Annie Sher; Evan Y Shi; Craig R Stumpf; Carly Christensen; Michael J Bonham; Shunyou Wang; Pingda Ren; Michael Martin; Katti Jessen; Morris E Feldman; Jonathan S Weissman; Kevan M Shokat; Christian Rommel; Davide Ruggero Journal: Nature Date: 2012-02-22 Impact factor: 69.504
Authors: A D Raval; D Thakker; A Vyas; M Salkini; S Madhavan; U Sambamoorthi Journal: Prostate Cancer Prostatic Dis Date: 2015-02-10 Impact factor: 5.554
Authors: Mike M Nguyen; Jessica A Martinez; Chiu-Hsieh Hsu; Mitchell Sokoloff; Robert S Krouse; Blake A Gibson; Raymond B Nagle; Howard L Parnes; Catherine Cordova; H-H Sherry Chow Journal: Eur J Cancer Prev Date: 2018-11 Impact factor: 2.497
Authors: Inaya Ahmed; Adam Ferro; Alan Cohler; John Langenfeld; Sujani G Surakanti; Joseph Aisner; Wei Zou; Bruce G Haffty; Salma K Jabbour Journal: J Thorac Dis Date: 2015-03 Impact factor: 2.895
Authors: Brian Winters; Stephen Plymate; Steven B Zeliadt; Sarah Holt; Xiaotun Zhang; Elaine Hu; Daniel W Lin; Colm Morrissey; Bryan Wooldridge; John L Gore; Michael P Porter; Jonathan L Wright Journal: Prostate Date: 2015-07-22 Impact factor: 4.104
Authors: Malte Rieken; Luis A Kluth; Evanguelos Xylinas; Harun Fajkovic; Andreas Becker; Pierre I Karakiewicz; Michael Herman; Yair Lotan; Christian Seitz; Paul Schramek; Mesut Remzi; Wolfgang Loidl; Karl Pummer; Richard K Lee; Talia Faison; Douglas S Scherr; Alexandra Kautzky-Willer; Alexander Bachmann; Ashutosh Tewari; Shahrokh F Shariat Journal: World J Urol Date: 2013-09-24 Impact factor: 4.226
Authors: E H Allott; M R Abern; L Gerber; C J Keto; W J Aronson; M K Terris; C J Kane; C L Amling; M R Cooperberg; P G Moorman; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2013-10-08 Impact factor: 5.554